Abstract
References
- Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-19 pandemic on cancer care. Nat Cancer 2020: 1-3.
- Lee S, Heo J. COVID-19 pandemic: a new cause of unplanned interruption of radiotherapy in breast cancer patients. Med Oncol 2021; 39: 5.
- Papautsky EL, Hamlish T. Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic. Breast Cancer Res Treat 2020; 184: 249-54.
- Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 2007; 68: 654-61.
- Coles CE, Aristei C, Bliss J, et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clin Oncol (R Coll Radiol) 2020; 32: 279-81.
- Göksel F, Güzle Adaş Y. Management of a radiation oncology clinic in a clean oncology hospital during the COVID-19 outbreak. J Surg Med 2020; 4: 925-9.
- Anacak Y, Onal C, Ozyigit G, et al. Changes in radiotherapy practice during COVID-19 outbreak in Turkey: A report from the Turkish Society for Radiation Oncology. Radiother Oncol 2020; 150: 43-5.
- Marschner S, Corradini S, Rauch J, et al. SARS-CoV-2 prevalence in an asymptomatic cancer cohort-results and consequences for clinical routine. Radiat Oncol 2020; 15: 165.
- Ning MS, McAleer MF, Jeter MD, et al. Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. Radiother Oncol 2020; 148: 252-7.
- Benk V, Joseph L, Fortin P, et al. Effect of delay in initiating radiotherapy for patients with early stage breast cancer. Clin Oncol (R Coll Radiol) 2004; 16: 6-11.
- Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJJJoco. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review 2003; 21: 555-63.
- Bese NS, Sut PA, Ober A. The effect of treatment interruptions in the postoperative irradiation of breast cancer. Oncology 2005; 69: 214-23.
- Gemici C, Yaprak G. Covid-19 outbreak in a major radiation oncology department; which lessons should be taken? Radiother Oncol 2020; 149: 107-8.
- Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086-94.
- Brunt AM, Haviland JS, Sydenham M, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol 2020; 38: 3261-72.
- Brunt AM, Wheatley D, Yarnold J, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol 2016; 120: 114-8.
- de Azambuja E, Trapani D, Loibl S, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open 2020; 5.
- Lutz ST, Chow EL, Hartsell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer 2007; 109: 1462-70.
- Tsoutsou PG, Koukourakis MI, Azria D, Belkacemi Y. Optimal timing for adjuvant radiation therapy in breast cancer: a comprehensive review and perspectives. Crit Rev Oncol Hematol 2009; 71: 102-16.
- Abdel-Rahman O. Impact of timeliness of adjuvant chemotherapy and radiotherapy on the outcomes of breast cancer; a pooled analysis of three clinical trials. Breast 2018; 38: 175-80.
Abstract
Aim: In this study; We wanted to examine the changes and delays in radiotherapy of all our breast cancer patients diagnosed with COVID-19
Material and Method: Radiotherapy delays of our breast cancer patients who had COVID-19 infection before and during radiotherapy between March 2020 and March 2021 were evaluated retrospectively.
Results: Sixteen of a total of 642 breast cancer patients, 472 operated and 165 metastatic, who underwent radiotherapy were diagnosed with COVID-19. All patients were women, ages were between 40 and 77 (mean 54.6). Five patients had a mastectomy, 8 had breast-conserving surgery, and 3 had breast cancer with bone metastases. Different radiotherapy schemes were applied at different treatment duration according to the clinical stage and disease status. The first breast cancer patient with COVID-19 infection was diagnosed on 27 June 2020. Our other patients were diagnosed from June to December (n=15) in 2020. Treatment of patients infected during radiotherapy was interrupted after a mean of 10 fractions (2-24 fractions) and treatment was started after a mean of 25 days (21-44 days). Post-operative patients who could not start treatment because they were SARS-CoV-2 PCR positive were able to start treatment after a mean of 22 days (14-30 days).
Conclusion: Radiotherapy could not be started at the recommended times for breast cancer patients infected with COVID-19 during the pandemic and the treatments had to be interrupted. Therefore, more care should be taken in the follow-up of these patients; should be considered as patients at risk for local recurrence and metastasis.
Keywords
References
- Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-19 pandemic on cancer care. Nat Cancer 2020: 1-3.
- Lee S, Heo J. COVID-19 pandemic: a new cause of unplanned interruption of radiotherapy in breast cancer patients. Med Oncol 2021; 39: 5.
- Papautsky EL, Hamlish T. Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic. Breast Cancer Res Treat 2020; 184: 249-54.
- Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 2007; 68: 654-61.
- Coles CE, Aristei C, Bliss J, et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clin Oncol (R Coll Radiol) 2020; 32: 279-81.
- Göksel F, Güzle Adaş Y. Management of a radiation oncology clinic in a clean oncology hospital during the COVID-19 outbreak. J Surg Med 2020; 4: 925-9.
- Anacak Y, Onal C, Ozyigit G, et al. Changes in radiotherapy practice during COVID-19 outbreak in Turkey: A report from the Turkish Society for Radiation Oncology. Radiother Oncol 2020; 150: 43-5.
- Marschner S, Corradini S, Rauch J, et al. SARS-CoV-2 prevalence in an asymptomatic cancer cohort-results and consequences for clinical routine. Radiat Oncol 2020; 15: 165.
- Ning MS, McAleer MF, Jeter MD, et al. Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. Radiother Oncol 2020; 148: 252-7.
- Benk V, Joseph L, Fortin P, et al. Effect of delay in initiating radiotherapy for patients with early stage breast cancer. Clin Oncol (R Coll Radiol) 2004; 16: 6-11.
- Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJJJoco. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review 2003; 21: 555-63.
- Bese NS, Sut PA, Ober A. The effect of treatment interruptions in the postoperative irradiation of breast cancer. Oncology 2005; 69: 214-23.
- Gemici C, Yaprak G. Covid-19 outbreak in a major radiation oncology department; which lessons should be taken? Radiother Oncol 2020; 149: 107-8.
- Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086-94.
- Brunt AM, Haviland JS, Sydenham M, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol 2020; 38: 3261-72.
- Brunt AM, Wheatley D, Yarnold J, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol 2016; 120: 114-8.
- de Azambuja E, Trapani D, Loibl S, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open 2020; 5.
- Lutz ST, Chow EL, Hartsell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer 2007; 109: 1462-70.
- Tsoutsou PG, Koukourakis MI, Azria D, Belkacemi Y. Optimal timing for adjuvant radiation therapy in breast cancer: a comprehensive review and perspectives. Crit Rev Oncol Hematol 2009; 71: 102-16.
- Abdel-Rahman O. Impact of timeliness of adjuvant chemotherapy and radiotherapy on the outcomes of breast cancer; a pooled analysis of three clinical trials. Breast 2018; 38: 175-80.
Details
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Research Articles |
| Authors | |
| Early Pub Date | March 24, 2022 |
| Publication Date | March 29, 2022 |
| Published in Issue | Year 2022 Volume: 4 Issue: 2 |
TR DİZİN ULAKBİM and International Indexes (1b)
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/3449/file/4924/show
Journal Indexes and Platforms:
TR Dizin ULAKBİM, Google Scholar, Crossref, Worldcat (OCLC), DRJI, EuroPub, OpenAIRE, Turkiye Citation Index, Turk Medline, ROAD, ICI World of Journal's, Index Copernicus, ASOS Index, General Impact Factor, Scilit.The indexes of the journal's are;
|
|
|
|
The platforms of the journal's are;
|
|
|
|
The indexes/platforms of the journal are;
TR Dizin Ulakbim, Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, ICI World of Journal's, Index Copernicus, Turk Medline, General Impact Factor, Scilit
EBSCO, DOAJ, OAJI is under evaluation.
Journal articles are evaluated as "Double-Blind Peer Review"